Module

HCV Therapy: What Will the Future Look Like?

Source: Hepatitis Annual Update 2008

HCV Therapy: What Will the Future Look Like?

Co-Chair: Mark S. Sulkowski, MD

Faculty:
David R. Nelson, MD

CME CREDIT INFORMATION

Release Date: 07/08/08

Expiration Date: 07/07/09

Physicians: maximum of 1.25 AMA PRA Category 1 Credit(s)™

Pharmacists: 1.4 contact hours (0.14 CEUs)

Registered Nurses: 1.4 Nursing CE credits

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe hepatitis C virology relevant to investigational agents for hepatitis C
Discuss new treatment efficacy data for investigational, targeted therapies for hepatitis C
Recall resistance data for investigational hepatitis C agents
Discuss data regarding the role of peginterferon and ribavirin in future hepatitis C treatment algorithms

Topics covered include:

Introduction
Targeted Anti-HCV Therapies
Protease Inhibitors
Polymerase Inhibitors
Therapies That Target Host Factors
Inhibitors of Viral Assembly and Release
Novel Interferons
Ribavirin Analogues
HCV Graveyard
Conclusions
Summary: Implications for Clinical Practice

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.